The challenge of an expanded therapeutic window in pulmonary hypertension

Nature Reviews Cardiology, Published online: 16 January 2020; doi:10.1038/s41569-020-0332-9Our understanding of the causes and consequences of pulmonary hypertension is limited. Consequently, its most distinctive forms with the worst prognosis have been the focus for diagnosis and treatment. We highlight the emerging challenge of reframing the prevalence and prognostic implications of pulmonary hypertension, focusing on the optimal therapeutic window to address the high mortality linked to this condition.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research

Related Links:

Conclusion Myocardial perfusion defects, both in RV and LV, occur even in asymptomatic or mildly symptomatic patients with Eisenmenger syndrome.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Authors: Boucly A, Savale L, Vuillard C, Turpin M, Jaïs X, Montani D, Humbert M, Sitbon O Abstract Right ventricular failure (RVF) is a common cause of admission to the intensive care unit and its presence is a major prognostic factor in acute pulmonary embolism (PE) and chronic pulmonary hypertension (PH). RVF results from an incapacity of the RV to adapt to an increase in afterload so it can become critical in acute PE and chronic PH. The presence of RVF in cases of acute PE with haemodynamic instability is an indication for thrombolytic therapy. RVF represents the most common cause of death in chronic PH. F...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
AbstractPulmonary hypertension (PH) has been described in myelofibrosis (MF), but it is rare and typically found in advanced disease. Although the etiology of PH in MF is unclear, early predictors may be detected by echocardiogram. The goals of our study were to evaluate the prevalence of PH as determined by echocardiography in a cohort of MF patients and to identify clinical risk factors for PH. We performed a retrospective review of MF patients from October 2015 to May 2017 at MD Anderson Cancer Center in the ambulatory clinic, and those with echocardiogram were included. Clinical, echocardiographic, and laboratory data ...
Source: Annals of Hematology - Category: Hematology Source Type: research
NEW BRUNSWICK, N.J., February 18, 2020 – Johnson &Johnson today announced that its Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health &Human Services, to seek treatment solutions for COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2 (also known as 2019-nCoV). This latest collaboration will enhance Janssen’s ongoing work with global partners to screen a library of existing antiviral m...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Condition:   Chronic Thromboembolic Pulmonary Hypertension Interventions:   Drug: Macitentan;   Drug: Placebo Sponsor:   Actelion Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: May 2020Source: Biomedicine &Pharmacotherapy, Volume 125Author(s): Juan Li, Min Jia, Manling Liu, Zhi Cao, Xinju Wang, Na Feng, Xiaoming Gu, Shumiao Zhang, Rong Fan, Haitao Guo, Yuemin Wang, Mingchao Liu, Jianming PeiAbstractκ-opioid receptor (κ-OR) plays a key role in preventing hypoxic pulmonary hypertension (HPH) development after activated by exogenous agonist U50,488H. Calcium sensing receptor (CaSR) activation induces HPH by promoting vasoconstriction and vascular remodeling. The activated κ-OR is reported to inhibit the expression of CaSR in pulmonary artery smooth muscle cell...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
We report central invasive haemodynamic parameters at rest and exercise during a 3 year follow‐up after HTx in a sub‐study of the SCandiavian Heart transplant Everolimus De novo stUdy with earLy calcineurin inhibitor avoidancE trial. We hypothesized that the nephroprotective properties, the less development of cardiac allograft vasculopathy (CAV), and the antifibrotic properties of EVR, in comparison with CNI‐based immunosuppression, would demonstrate favourable invasive haemodynamic profiles in patients at rest and during exercise.Methods and resultsNinety of 115 HTx recipients randomized to EVR or CNI treatment per...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
DISCUSSION:  In patients with ESRD, PH is frequently associated with fluid retention as shown by bioimpedance spectroscopy. After adjustment of fluid to normal levels, PH was confirmed by invasive test in nearly 4 % of cases. PMID: 32053839 [PubMed - as supplied by publisher]
Source: Pneumologie - Category: Respiratory Medicine Tags: Pneumologie Source Type: research
Dear Editor,
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Letter to the Editor Source Type: research
The effect of activated κ-opioid receptor (κ-OR) on the role of calcium sensing receptor (CaSR) in preventing hypoxic pulmonary hypertension development. Biomed Pharmacother. 2020 Feb 14;125:109931 Authors: Li J, Jia M, Liu M, Cao Z, Wang X, Feng N, Gu X, Zhang S, Fan R, Guo H, Wang Y, Liu M, Pei J Abstract κ-opioid receptor (κ-OR) plays a key role in preventing hypoxic pulmonary hypertension (HPH) development after activated by exogenous agonist U50,488H. Calcium sensing receptor (CaSR) activation induces HPH by promoting vasoconstriction and vascular remodeling. The activated...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
More News: Cardiology | Heart | Hypertension | Pulmonary Hypertension